Business Wire

Radial: EU Retailers Failing to Meet Customer Expectations beyond the Point of Purchase

Del

Today Radial, the omnichannel technology solutions company, releases its annual eDelivery Index 2017, highlighting the hidden customer service failings of retailers across the UK, Italy, Germany and Spain.

In the Age of Immediacy, where a taxi can be ordered in minutes, movies streamed in seconds and consumers can receive goods on next or same day delivery – consumer expectation is high. Despite this, the research has revealed that only half of retailers offer an express delivery option, whilst a paltry 6% offer same day delivery.

Demand for Now

Given this Demand for Now, the research reveals that when it comes to delivery and returns consumer convenience is a top priority. In terms of delivery choices, many retailers have caught on to the advantages of offering flexible options, with 2.7 options available on average – while the UK firmly leads the way with 4.4 delivery options.

However, charges on any of these options will soon be a deterrent to today’s entitled customer - with findings that 79% of retailers now offer free standard home delivery, and 95% offer free Click & Collect as an alternative to paid postal service.

Missed Opportunity with Click & Collect

Click & Collect remains popular across all countries with 95% of retailers offering the service, as it not only provides accessibility for the customer but also enables retailers to benefit from the additional footfall of driving customers to stores. Yet despite the obvious cost and flexibility advantages, few retailers are utilising in-store stock to service consumer orders - as indicated by the closely matching local average speeds of Standard home delivery with 3.1 days and Click & Collect with 3.2 days. Utilising this in-store stock will not only cater to the immediacy that many customers desire, but would also drive significant cost reductions in serving such orders.

The Evolution of Click & Collect

As an alternative trend, the research shows that delivery options now extend beyond Click & Collect, with on average 34% of retailers also offering convenience stores. This is a serious competitor issue for non-local retailers with 70% failing to provide this option.

Ben Willis, Managing Director International at Radial comments: “This research shows that for European retailers today, a ubiquitous omnichannel offering is simply not the reality. These findings are a proof point that today’s retailers need to reassess their customer experience strategy to look at the bigger picture.

The ubiquity of online and mobile commerce means that brand competition has reached previously unimaginable levels and is threatening to destroy customer loyalty altogether. The likes of Amazon have created consumer expectation for a whole new level of customer experience - and this needs to be considered when it comes to delivery and returns. For retailers to deliver a true omnichannel experience they need to consider how they engage with customers beyond the point of purchase, prioritise delivery and returns that meets the needs for customers – ensuring repeat business.

Lastly, a much-underestimated aspect of the customer journey is consumer convenience and costliness of returns. Research shows, brands offer a satisfactory selection of on average 1.9 return options; however, they are lacking in offering in-store return options. With only 52% of retailers providing this free avenue to consumers, the research suggests that retailers are placing immediate profits above long-term revenue. The in-store return method offers a significant opportunity to cut down the cost of returns by promoting exchanges and refunds and assimilating in-store returns directly into store inventory.

ENDS

About Radial’s European eDelivery Index

The full report can be downloaded here

If local or non-local retailer is not specified the figure is based on the average from 150 of Europe’s biggest online retailers, both local and non-local.

About Radial

Radial is the leader in omnichannel commerce technology and operations, enabling brands and retailers to profitably exceed retail customer expectations. Radial's technical, powerful omnichannel solutions connect supply and demand through efficient fulfilment and transportation options, intelligent fraud detection, payments, and tax systems, and personalized customer care services.

Hundreds of retailers and brands confidently partner with Radial to simplify their post-click commerce and improve their customer experiences. Radial brings flexibility and scalability to their supply chains and optimizes how, when and where orders go from desire to delivery. Learn how we work with you at www.radial.com.

Learn more at www.radial.com and connect with the team at TwitterLinkedIn, and our blog.

Contact information

For more information, please contact:
CubanEight
Siobhan Eyres or Shannon Tweed
Tel: 01869 715090
Email: radial@cubaneight.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an